close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enGene Therapeutics Inc. - Common Stock (NQ:ENGN)

1.705 -0.035 (-2.01%)
Streaming Delayed Price Updated: 1:03 PM EDT, Jun 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about enGene Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge ↗
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors. 
Via The Motley Fool
News headline image
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean ↗
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics. 
Via The Motley Fool
News headline image
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers. 
Via The Motley Fool
Topics Regulatory Compliance
Unusual volume stocks are being observed in Monday's session. ↗
Via Chartmill
News headline image
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain ↗
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk... 
Via MarketBeat
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Thursday? ↗
Via Chartmill
News headline image
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
From enGene Therapeutics Inc.
Via Business Wire
News headline image
enGene Announces Name Change to enGene Therapeutics Inc.
From enGene Therapeutics Inc.
Via Business Wire
News headline image
This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials. 
Via The Motley Fool
News headline image
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in Upcoming Investor Conferences
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Reports Full Year 2025 Financial Results and Provides Business Update
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
From enGene Holdings Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
From enGene Holdings Inc.
Via Business Wire
News headline image
enGene Announces Proposed Public Offering of Common Shares
From enGene Holdings Inc.
Via Business Wire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗
 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today